Lipo-B is an injectable blend commonly offered by compounding pharmacies and medical spas, typically combining “lipotropic” agents (usually methionine, inositol, and choline — often called MIC) with vitamin B12. It is marketed primarily for weight-loss support alongside diet and exercise programs. Formulations are not standardized: composition and dosing vary meaningfully from one clinic or compounding pharmacy to the next.
Research snapshot
| Peptide category | Compounded lipotropic/vitamin injection blend (not a peptide product) |
| Primary research interest | Marketed for weight-management support alongside diet and exercise; component-level metabolic roles |
| Highest available evidence | Tier 6 — no clinical trial of this specific combined formulation was identified; component ingredients have their own separate nutritional evidence |
| Human research available | No trial of the combined shot as sold; individual components (methionine, inositol, choline, B12) have general nutritional/metabolic literature |
| Development status | Not a formulated drug product; a compounding-pharmacy preparation that varies by clinic |
| Regulatory status | Not an FDA-approved drug product; prepared under state pharmacy compounding rules |
| Last reviewed | September 2026 |
Technical identity (composition)
| Primary name | Lipo-B (vendor/clinic name) |
| Composition | Methionine, inositol, and choline (the “MIC” combination) plus vitamin B12, sometimes with small amounts of other B vitamins (such as B6 or B1) |
| Share of vial by mass | Not standardised — exact ratios and concentrations differ between compounding pharmacies and clinics; not chemically identical from one provider to another |
| Peptide sequence | Not applicable — this is a vitamin/amino-acid blend, not a peptide |
| Molecular formula | Not applicable — a multi-component mixture, not a single molecular entity |
| CAS Registry Number | Not applicable — no CAS number is assigned to the combination itself |
| Chemical modifications | Not applicable — unmodified nutrients/vitamins |
| Developer or originator | Not applicable — a compounding-pharmacy/clinic preparation, not a developed drug product |
| Development status | Not in formal development; no INN, no approved status |
What is typically in it
Vendor and clinic descriptions of Lipo-B most commonly list methionine, inositol, and choline (the “MIC” combination) plus vitamin B12, sometimes with small amounts of other B vitamins (such as B6 or B1) added. Methionine and choline are involved in fat and lipid metabolism in the liver; inositol is involved in cell signaling and has been marketed for mood and metabolic support; B12 is added primarily for its association with energy and metabolism.
Because Lipo-B is typically prepared by compounding pharmacies rather than manufactured as a single standardized product, exact ingredient ratios, concentrations, and which specific B vitamins are included differ meaningfully between clinics and compounders. A given patient’s “Lipo-B” shot at one med spa is not guaranteed to be chemically identical to another clinic’s product sold under the same name.
Why the name became popular / clinical use
The individual components of Lipo-B (methionine, inositol, choline, B12) each have a long history of use in mainstream and alternative medicine for liver and lipid metabolism support, and lipotropic injections have been marketed by weight-loss clinics for decades, often alongside medically supervised diet programs. The “Lipo-B” name appears to function primarily as a clinic marketing label for this MIC-plus-B12 combination rather than as a name tied to a specific clinical trial or regulatory approval.
Has the combination itself been studied?
The individual components of Lipo-B — methionine, choline, inositol, and B12 — each have some published human and animal research behind their individual roles in lipid and liver metabolism, and B12 itself has strong deficiency-treatment evidence (see the separate methylcobalamin/B12 entry on this site). However, PeptideBlog.net did not identify a published, controlled clinical trial evaluating the specific combined Lipo-B injectable formulation itself (as opposed to its individual ingredients) for weight loss or any other outcome. Combining individually studied ingredients does not, by itself, establish that the combination has been clinically validated as a weight-loss treatment.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported by compounding pharmacies, med spas, and clinic marketing. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Reported clinic and compounding-pharmacy formulations
Clinic and compounding-pharmacy materials commonly describe formulations in the range of approximately 25 mg methionine, 50 mg inositol, and 50 mg choline, combined with roughly 100 mcg vitamin B12 per injection, though specific concentrations vary by compounder. This is vendor/practitioner-reported information (Tier 5/6), not a standardized clinical dose, and formulations differ meaningfully between sources.
Reported use patterns
Weight-loss clinics and med spas commonly describe weekly intramuscular injections, often as an adjunct to a supervised diet and exercise program, sometimes continued for several weeks to months. This use pattern is practitioner/vendor-reported and not derived from a controlled trial of the Lipo-B formulation itself.
Combinations and related research
Formally studied: none identified for the Lipo-B combination as a whole. Mechanistically plausible: individual components (methionine, choline, inositol, B12) each have some biological rationale for a role in fat/lipid metabolism, drawn from separate lines of research on each ingredient. Practitioner-reported: weight-loss clinics commonly pair Lipo-B injections with prescription weight-loss medications, calorie-restricted diets, or exercise programs; these combinations are clinic protocols, not studied combinations. Community-reported: online discussion of Lipo-B use is relatively limited compared to more heavily discussed peptides, and is largely secondhand from clinic marketing.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Weight-loss support adjunct (clinic/med-spa use) | Intramuscular injection | MIC base + ~100 mcg B12 | Weekly | Several weeks to months, per clinic protocol |
Weight-loss clinics and compounding pharmacies commonly describe a weekly intramuscular injection combining methionine, inositol, choline, and B12, typically around 25 mg methionine, 50 mg inositol, 50 mg choline, and roughly 100 mcg B12 per injection, used alongside a supervised diet and exercise program.
This is vendor/practitioner-reported information; exact composition and dosing are not standardized and vary by compounder, and no controlled trial of the combined product was identified.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Reported side effects associated with lipotropic injections generally include injection-site soreness, and, less commonly, gastrointestinal upset. Because these are typically compounded (not FDA-approved, batch-tested finished drug) products, formulation consistency, sterility, and accurate labeling depend on the individual compounding pharmacy’s practices, which is a general risk of compounded injectables rather than something specific to any one ingredient. No systematic, formulation-specific safety trial for Lipo-B was identified.
Regulatory and developmental status
Lipo-B is not an FDA-approved drug product; it is typically prepared by compounding pharmacies under state pharmacy regulations rather than as a single, federally approved formulation. Its individual ingredients (B12, choline, inositol, methionine) have varying regulatory recognition individually (B12 being the most established), but the combined injectable product itself has no FDA approval for weight loss or any other indication. Status verified as of the review date below.
Frequently asked questions
What is Lipo-B?
Lipo-B is a compounded injectable blend, typically combining methionine, inositol, and choline (MIC) with vitamin B12, marketed by weight-loss clinics and med spas for fat-metabolism support.
Does Lipo-B cause weight loss on its own?
No controlled clinical trial of the combined formulation was identified. It is typically marketed as an adjunct to diet and exercise programs, not as a standalone weight-loss treatment, and the combination itself has not been clinically validated.
Is the composition the same at every clinic?
No. Because Lipo-B is generally compounded rather than mass-manufactured as a single standardized product, exact ingredients and doses vary between compounding pharmacies and clinics.
What dosage commonly circulates for Lipo-B?
Clinic materials commonly describe roughly 25 mg methionine, 50 mg inositol, 50 mg choline, and about 100 mcg B12 per injection, given weekly, but this varies by compounder and is not a standardized clinical dose.
Is Lipo-B FDA approved?
No. It is a compounded product, not an FDA-approved drug formulation.
Bottom line
Lipo-B is a widely marketed compounded injectable combining lipotropic agents and B12, whose individual ingredients each have some independent research behind their metabolic roles, but whose combined formulation has not itself been evaluated in a published clinical trial. Composition and dosing are not standardized across sources, and the combination should not be assumed to be a clinically validated weight-loss treatment simply because its components are individually studied.